Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia

AIDS

Volumn 27, Issue 15, 2013, Pages 2425-2430

  Assoumou, Lambert ^a,b   Katlama, Christine ^a,b,c   Viard, Jean Paul ^d   Bentata, Michelle ^e   Simon, Anne ^c   Roux, Christian ^f   Kolta, Sami ^f   Costagliola, Dominique ^a,b   Rozenberg, Sylvie ^g  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e AVICENNE HOSPITAL   (France)

^f Service de Médecines Internes ^*  (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antiretroviral therapy; Bone mineral density; HIV; Osteopenia; Osteoporosis; Smallest detectable difference; Tenofovir

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; COMBINED ANTIRETROVIRAL THERAPY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SIDE EFFECT;

ABSORPTIOMETRY, PHOTON; ADENINE; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; HIP; HIV INFECTIONS; HIV-1; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RISK FACTORS;

EID: 84884500081     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32836378c3     Document Type: Article

References (32)

1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929-1936.
2. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21:617-623.
3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
4. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004; 19:402-409.
5. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24:2827-2833.
6. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-1923.
7. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395-402.
8. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-67.
9. Briot K, Kolta S, Flandre P, Boue F, Ngo Van P, Cohen-Codar I, et al. Prospective one-year bone loss in treatment-naive HIV+ men and women on single or multiple drug HIV therapies. Bone 2011; 48:1133-1139.
10. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23:817-824.
11. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
12. Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curie M, Goyenechea A, Fernandez-Guerrero M. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudiine plus abacavir or lopinavir/ritonavir. HIV Med 2008; 9:89-95.
13. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-1376.
14. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
15. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Bone mineral density remains stable in HAARTtreated HIV-infected men over 2 years. Clin Endocrinol 2007; 67:270-275.
16. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490.
17. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-1280.
18. Mary-Krause M, Viard JP, Ename-Mkoumazok B, Bentata M, Valantin MA, Missy P, et al. Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. J Clin Densitom 2012; 15:422-433.
19. Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, et al. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). AIDS Res Hum Retroviruses 2012; 28:972-980.
20. Kolta S, Ravaud P, Fechtenbaum J, Dougados M, Roux C. Follow-up of individual patients on two DXA scanners of the same manufacturer. Osteoporos Int 2000; 11:709-713.
21. Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res 1999; 14:1449-1456.
22. Faulkner KG. Bone densitometry: choosing the proper skeletal site to measure. J Clin Densitom 1998; 1:279-285.
23. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994; 9:1503-1514.
24. Janssen KJM, Donders ART, Harrell FE, Vergouwe Y, Chen QX, Grobbee DE, Moons KGM. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol 2010; 63:721-727.
25. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18:681-694.
26. Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
27. Cazanave C, Lawson-Ayayi S, Barthe N, Uwamaliya-Nziyumvira B, Kpozehouen A, Mehsen N, et al. Changes in bone mineral density: 2 year follow-up of the ANRS CO3 Aquitaine cohort. 17th Conference on Retroviruses and Opportunistic infections. San Francisco2010.
28. Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis 2010; 23:1-8.
29. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-972.
30. Ofotokun I, Weitzmann N, Vunnava A, Sheth A, Villinger F, Zhou J, et al. HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS. 18th Conference on Retroviruses and Opportunistic Infections. Boston2011.
31. Masia M, Padilla S, Robledano C, Lopez N, Ramos JM, Gutierrez F. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses 2012; 28:242-246.
32. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002; 13:105-112.